Skip to main content
. 2022 Nov 14;12:1046373. doi: 10.3389/fcimb.2022.1046373

Table 2.

Characteristics of patients with ESKD.

Characteristics Total (n=95) LTBI (n=23) Non-LTBI (n=72) p value
Age, years 44.30 ± 11.54 51.95 ± 15.84 54.08 ± 15.77 0.463
Male sex 56 (58.95) 13 (56.52) 43 (59.72) 0.786
BMI, kg/m2 23.01 ± 4.19 23.25 ± 3.96 23.64 ± 4.41 0.619
Cause of CKD 0.776
 Diabetes mellitus 8 (8.42) 2 (8.69) 6 (8.33)
 Hypertension 2 (2.10) 0 (0.00) 2 (2.77)
 Chronic glomerulonephritis 14 (14.73) 2 (8.69) 12 (16.67)
 Others 5 (5.26) 1 (4.34) 4 (5.55)
 Unknown 66 (69.47) 18 (78.26) 48 (66.67)
Comorbidities
 Diabetes mellitus 14 (14.73) 2 (8.69) 12 (16.67) 0.348
 Hypertension 85 (89.47) 20 (86.95) 65 (90.27) 0.651
 ASCVD 8 (8.42) 1 (4.34) 7 (9.72) 0.410
 HIV 1 (1.05) 0 (0.00) 1 (1.38) 0.567
Receiving immunosuppressants 3 (3.15) 1 (4.34) 2 (2.77) 0.708
BCG vaccination 94 (98.94) 23 (1.00) 71 (98.61) 0.570
History of TB infection 3 (3.15) 0 (0.00) 3 (4.16) 0.320
Current smoking 6 (6.31) 3 (13.04) 3 (4.16) 0.128
Current alcohol drinking 6 (6.31) 4 (17.39) 2 (2.77) 0.012
Renal replacement therapy 0.031
 Hemodialysis 76 (80.00) 22 (28.94) 54 (71.05)
 Peritoneal dialysis 19 (20.00) 1 (5.26) 18 (94.73)

Data are presented as mean ± standard deviation or n (%).

ASCVD, atherosclerotic cardiovascular disease; BCG, bacillus Calmette–Guérin; BMI, body mass index; CKD, chronic kidney disease; ESKD, end-stage kidney disease; HIV, human immunodeficiency virus; LTBI, latent tuberculosis infection; TB, tuberculosis.